WO2003004097A1 - Empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos en la elaboración de un medicamento para potenciar el efecto de otros fármacos en el tratamiento de la disfunción eréctil - Google Patents
Empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos en la elaboración de un medicamento para potenciar el efecto de otros fármacos en el tratamiento de la disfunción eréctil Download PDFInfo
- Publication number
- WO2003004097A1 WO2003004097A1 PCT/ES2002/000325 ES0200325W WO03004097A1 WO 2003004097 A1 WO2003004097 A1 WO 2003004097A1 ES 0200325 W ES0200325 W ES 0200325W WO 03004097 A1 WO03004097 A1 WO 03004097A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- effects
- phosphodiesterase
- nitric oxide
- apomorphine
- Prior art date
Links
- 0 *c(c(O)c1)cc(O)c1S(O)(=O)=O Chemical compound *c(c(O)c1)cc(O)c1S(O)(=O)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of derivatives of 2,5-dihydroxybenzenesulfonic acids of general formula (I), in the elaboration of medicaments useful in therapeutics to enhance the effects of phosphodiesterase-5 inhibitors including sildenafil, vardenafil and IC- 351, of apomorphine, of the donors of nitric oxide including amyl nitrate, nitroglycerin, nitroprusside, nitrosothiols and nicorandyl, of compounds that increase the level of cyclic GMP in penile tissue and of other compounds intended to promote penile erection in the man.
- phosphodiesterase-5 inhibitors including sildenafil, vardenafil and IC- 351, of apomorphine
- the donors of nitric oxide including amyl nitrate, nitroglycerin, nitroprusside, nitrosothiols and nicorandyl, of compounds that increase the level of cyclic G
- the present invention relates to the use of derivatives of 2,5-dihydroxybenzenesulfonic acids in the preparation of medicaments useful in therapeutics to enhance the effects of phosphodiesterase-5 inhibitors including sildenafil, vardenafil and IC-351, of apomorphine, of the donors of nitric oxide including amyl nitrate, nitroglycerin, nitroprusside, nitrosothiols and nicorandil, of the compounds that increase the level of cyclic GMP in penile tissue and of other compounds intended to promote penile erection in man.
- phosphodiesterase-5 inhibitors including sildenafil, vardenafil and IC-351, of apomorphine, of the donors of nitric oxide including amyl nitrate, nitroglycerin, nitroprusside, nitrosothiols and nicorandil, of the compounds that increase the level of cyclic GMP in penile tissue and of other compounds intended
- R represents a hydrogen atom or a sulfonate group (S0 3 ⁇ );
- B represents a calcium ion (Ca ++ ) or a diethylammonium group [H 2 N + (C 2 H 5 ) 2 ];
- n represents 1 or 2; and
- m represents 1 or 2.
- the resistance arteries of the penis were dissected by carefully removing the surrounding trabecular tissue and sectioned into 2 mm arterial segments in length, which were placed on two 40 ⁇ m diameter wires in a Halpern-Mulvany myograph (JP Trading, Aarhus, Denmark) for the recording of isometric tension.
- the chambers contained physiological solution (PSS) continuously bubbled with a mixture of 95% 0 2 /5% C0 2 to oxygenate and maintain a pH of 7.4.
- PES physiological solution
- the arteries contracted with 1 ⁇ M norepinephrine and the relaxing responses were evaluated after the addition on the chambers of cumulative amounts of the different compounds.
- TSE Transmural electrical stimulation
- Calcium dobesilate at a concentration of 10 ⁇ M statistically significantly increases the relaxation produced by electrical stimulation at increasing frequencies of nitrile terminations in resistance arteries of the human penis (fig 3). This effect is similar and even greater than that produced by sildenafil at a concentration of 10 nM (fig 4).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0400924A HUP0400924A3 (en) | 2001-07-02 | 2002-07-01 | Use of 2,5-dihydroxybenzenesulfphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
EP02745439A EP1413332B1 (en) | 2001-07-02 | 2002-07-01 | Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
MXPA04000007A MXPA04000007A (es) | 2001-07-02 | 2002-07-01 | Empleo de derivados de acidos 2,5-dihicroxibenceno-sulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. |
CA002453572A CA2453572A1 (en) | 2001-07-02 | 2002-07-01 | The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction |
BR0211315-5A BR0211315A (pt) | 2001-07-02 | 2002-07-01 | Uso de derivados de ácido 2,5-diidroxibenzeno-sulfÈnicos na elaboração de um produto medicinal para aumentar o efeito de outros medicamentos utilizados no tratamento de disfunção erétil |
DE60230629T DE60230629D1 (de) | 2001-07-02 | 2002-07-01 | Verwendung von 2,5-dihydroxybenzolsulfonsäure-derivaten bei der herstellung eines medikaments zur verstärkung der wirkung anderer arzneimittel zur behandlung der erektilen dysfunktion |
JP2003510106A JP2005501031A (ja) | 2001-07-02 | 2002-07-01 | 勃起障害の治療における他の薬物の効果を増強するために用いる医薬の生産における2,5−ジヒドロキシベンゼンスルホン酸誘導体の使用 |
US10/482,457 US20040143010A1 (en) | 2001-07-02 | 2002-07-01 | Use of derivatives of 2, 5-dihydroxybenzenesulphonic acid derivatives in the production of a medication used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
PL02367766A PL367766A1 (en) | 2001-07-02 | 2002-07-01 | Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
NO20040007A NO20040007L (no) | 2001-07-02 | 2004-01-02 | Anvendelse av 2,5-dihydroksybenzensulfonsyrederivater ved fremstilling av medikament for a fremme effekten av andre medikamenter ved behandling av erektil dysfunksjon |
US11/641,269 US20070197543A1 (en) | 2001-07-02 | 2006-12-19 | Use of derivatives of 2, 5-dihydroxyb enzene-sulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200101535A ES2180446B1 (es) | 2001-07-02 | 2001-07-02 | Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. |
ESP0101535 | 2001-07-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/641,269 Division US20070197543A1 (en) | 2001-07-02 | 2006-12-19 | Use of derivatives of 2, 5-dihydroxyb enzene-sulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003004097A1 true WO2003004097A1 (es) | 2003-01-16 |
Family
ID=8498259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2002/000325 WO2003004097A1 (es) | 2001-07-02 | 2002-07-01 | Empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos en la elaboración de un medicamento para potenciar el efecto de otros fármacos en el tratamiento de la disfunción eréctil |
Country Status (14)
Country | Link |
---|---|
US (2) | US20040143010A1 (es) |
EP (1) | EP1413332B1 (es) |
JP (1) | JP2005501031A (es) |
AR (1) | AR036124A1 (es) |
AT (1) | ATE419012T1 (es) |
BR (1) | BR0211315A (es) |
CA (1) | CA2453572A1 (es) |
DE (1) | DE60230629D1 (es) |
ES (2) | ES2180446B1 (es) |
HU (1) | HUP0400924A3 (es) |
MX (1) | MXPA04000007A (es) |
NO (1) | NO20040007L (es) |
PL (1) | PL367766A1 (es) |
WO (1) | WO2003004097A1 (es) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2222831A1 (es) * | 2003-07-30 | 2005-02-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+. |
US8282967B2 (en) | 2005-05-27 | 2012-10-09 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
US8981139B2 (en) | 2011-02-28 | 2015-03-17 | The University Of North Carolina At Chapel Hill | Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2208123A1 (es) * | 2002-11-29 | 2004-06-01 | Laboratorios Del Dr. Esteve, S.A. | Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento. |
EP1676573A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor |
CN109678764A (zh) * | 2018-12-05 | 2019-04-26 | 湖北广辰药业有限公司 | 一种羟苯双磺酸及其钙盐和制备方法 |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3681503A (en) * | 1970-04-17 | 1972-08-01 | Om Lab Sa | Method for combating disturbances of the lipid content of the blood |
US4252821A (en) * | 1979-12-07 | 1981-02-24 | Laboratoires Om Societe Anonyme | Method for treating ulcers |
FR2511598A1 (fr) * | 1981-08-24 | 1983-02-25 | Gauri Kailash | Produit pharmaceutique contenant une substance activant la circulation sanguine, en combinaison avec un concentrat de dialyse de sang de veau deproteine |
RU1776408C (ru) * | 1990-08-13 | 1992-11-23 | Одесский Медицинский Институт Им.Н.И.Пирогова | Способ лечени гломерулонефрита |
WO1997037647A1 (fr) * | 1996-04-03 | 1997-10-16 | Laboratorios Del Dr. Esteve, S.A. | Utilisation des derives 2,5-dihydroxybenzenesulfoniques pour la fabrication de medicaments destines a la normalisation de la fonction endotheliale, pour le traitement de la dysfonction sexuelle et des complications vasculaires du diabete, ainsi que des troubles vasculaires d'origine endotheliale |
WO1998029103A2 (en) * | 1996-12-30 | 1998-07-09 | Biogal Gyógyszergyár Rt | Use of calcium dobesilate for the manufacture of a medicament for the treatment of embryonic retardation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513007A (en) * | 1983-05-03 | 1985-04-23 | Laboratoires Om Sa | Method for treating heart disease |
US6403643B1 (en) * | 1997-04-03 | 2002-06-11 | Laboratories Del Dr. Esteve, S.A. | Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function |
US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
-
2001
- 2001-07-02 ES ES200101535A patent/ES2180446B1/es not_active Expired - Fee Related
-
2002
- 2002-07-01 US US10/482,457 patent/US20040143010A1/en not_active Abandoned
- 2002-07-01 PL PL02367766A patent/PL367766A1/xx not_active Application Discontinuation
- 2002-07-01 BR BR0211315-5A patent/BR0211315A/pt not_active IP Right Cessation
- 2002-07-01 WO PCT/ES2002/000325 patent/WO2003004097A1/es active Application Filing
- 2002-07-01 ES ES02745439T patent/ES2318023T3/es not_active Expired - Lifetime
- 2002-07-01 EP EP02745439A patent/EP1413332B1/en not_active Expired - Lifetime
- 2002-07-01 AT AT02745439T patent/ATE419012T1/de not_active IP Right Cessation
- 2002-07-01 DE DE60230629T patent/DE60230629D1/de not_active Expired - Fee Related
- 2002-07-01 HU HU0400924A patent/HUP0400924A3/hu unknown
- 2002-07-01 MX MXPA04000007A patent/MXPA04000007A/es not_active Application Discontinuation
- 2002-07-01 JP JP2003510106A patent/JP2005501031A/ja active Pending
- 2002-07-01 CA CA002453572A patent/CA2453572A1/en not_active Abandoned
- 2002-07-01 AR ARP020102472A patent/AR036124A1/es not_active Application Discontinuation
-
2004
- 2004-01-02 NO NO20040007A patent/NO20040007L/no not_active Application Discontinuation
-
2006
- 2006-12-19 US US11/641,269 patent/US20070197543A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3681503A (en) * | 1970-04-17 | 1972-08-01 | Om Lab Sa | Method for combating disturbances of the lipid content of the blood |
US4252821A (en) * | 1979-12-07 | 1981-02-24 | Laboratoires Om Societe Anonyme | Method for treating ulcers |
FR2511598A1 (fr) * | 1981-08-24 | 1983-02-25 | Gauri Kailash | Produit pharmaceutique contenant une substance activant la circulation sanguine, en combinaison avec un concentrat de dialyse de sang de veau deproteine |
RU1776408C (ru) * | 1990-08-13 | 1992-11-23 | Одесский Медицинский Институт Им.Н.И.Пирогова | Способ лечени гломерулонефрита |
WO1997037647A1 (fr) * | 1996-04-03 | 1997-10-16 | Laboratorios Del Dr. Esteve, S.A. | Utilisation des derives 2,5-dihydroxybenzenesulfoniques pour la fabrication de medicaments destines a la normalisation de la fonction endotheliale, pour le traitement de la dysfonction sexuelle et des complications vasculaires du diabete, ainsi que des troubles vasculaires d'origine endotheliale |
WO1998029103A2 (en) * | 1996-12-30 | 1998-07-09 | Biogal Gyógyszergyár Rt | Use of calcium dobesilate for the manufacture of a medicament for the treatment of embryonic retardation |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Derwent World Patents Index; AN 1993-402392, XP002963114 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005013962A1 (en) * | 2003-07-30 | 2005-02-17 | Laboratorios Del Dr. Esteve S.A. | Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator |
JP2007500163A (ja) * | 2003-07-30 | 2007-01-11 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | 2,5−ジヒドロキシベンゼンスルホン酸化合物およびカリウムイオンチャンネル調節剤を含む活性物質組合せ |
ES2222831A1 (es) * | 2003-07-30 | 2005-02-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+. |
US9403852B2 (en) | 2005-05-27 | 2016-08-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8282967B2 (en) | 2005-05-27 | 2012-10-09 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US11691995B2 (en) | 2005-05-27 | 2023-07-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8956658B2 (en) | 2005-05-27 | 2015-02-17 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8962029B2 (en) | 2005-05-27 | 2015-02-24 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US9403851B2 (en) | 2005-05-27 | 2016-08-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US9737561B2 (en) | 2009-08-21 | 2017-08-22 | Novan, Inc. | Topical gels and methods of using the same |
US9526738B2 (en) | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US9919072B2 (en) | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US10376538B2 (en) | 2009-08-21 | 2019-08-13 | Novan, Inc. | Topical gels and methods of using the same |
US11583608B2 (en) | 2009-08-21 | 2023-02-21 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
US9713652B2 (en) | 2011-02-28 | 2017-07-25 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing S-nitrosothiol-modified silica particles and methods of making the same |
US8981139B2 (en) | 2011-02-28 | 2015-03-17 | The University Of North Carolina At Chapel Hill | Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
DE60230629D1 (de) | 2009-02-12 |
ES2318023T3 (es) | 2009-05-01 |
ES2180446B1 (es) | 2004-01-16 |
ATE419012T1 (de) | 2009-01-15 |
US20070197543A1 (en) | 2007-08-23 |
MXPA04000007A (es) | 2004-05-21 |
PL367766A1 (en) | 2005-03-07 |
BR0211315A (pt) | 2004-09-28 |
HUP0400924A3 (en) | 2007-11-28 |
HUP0400924A2 (hu) | 2004-07-28 |
EP1413332A1 (en) | 2004-04-28 |
JP2005501031A (ja) | 2005-01-13 |
ES2180446A1 (es) | 2003-02-01 |
US20040143010A1 (en) | 2004-07-22 |
CA2453572A1 (en) | 2003-01-16 |
EP1413332B1 (en) | 2008-12-31 |
AR036124A1 (es) | 2004-08-11 |
NO20040007L (no) | 2004-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR036448A1 (es) | Composiciones farmaceuticas de conjugados droga insulina-oligomeros, y metodos para tratar las enfermedades con los mismos | |
KR19990044182A (ko) | 말초 활성 통각과민 치료용 아편제 | |
ES2318023T3 (es) | Uso de derivados de acidos 2,5-dihidroxibenceno-sulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. | |
JP2008533140A (ja) | 術後鎮痛剤の低減 | |
KR20010071283A (ko) | 유기 질산염 또는 유기 이질산염을 함유하는 발기부전치료용 조성물 | |
ATE414522T1 (de) | Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure | |
RU2007133435A (ru) | Способ комбинированного лечения и применимые для этого сочетания лекарственных средств | |
EP3158990A1 (en) | Formulation for release of nitric oxide | |
ATE382354T1 (de) | Präoperative behandlung von postoperativen schmerzen | |
US10716805B2 (en) | Formulation for release of nitric oxide | |
RU2413548C1 (ru) | Способ лечения остеоартроза коленного сустава | |
CN104324018A (zh) | 广藿香醇在制备男性性功能障碍药物或保健品中的应用 | |
RU2009112724A (ru) | Циклические сульфоны в качестве митохондриальных натрий-кальциевых обменников | |
WO2015026851A1 (en) | Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate | |
RU2459642C2 (ru) | Способ лечения травматических невропатий | |
KR100324447B1 (ko) | 아티파메졸을 함유하는 남성 성기능 장애 치료용 약학적 조성물 | |
RU2173988C1 (ru) | Лекарственная композиция для локального лечения доброкачественных опухолей и предраковых заболеваний кожи | |
ES2383858B1 (es) | Compuestos marinos antagonistas de los canales de calcio para el tratamiento de enfermedades cardiovasculares. | |
Baine | The Effects of Sex on Spinal Cord Injury Recovery Following Noxious Input | |
CN115745890A (zh) | 一种酯键化合物及其制备方法和应用、镇痛药物 | |
UA44987C2 (uk) | Лікарська композиція "арф" для локального лікування доброякісних пухлин і передракових захворювань шкіри | |
BRPI0705221A2 (pt) | dispositivos para a sìntese e incorporação pré-aplicação de doadores de óxido nìtrico em composições macromoleculares | |
RU2010154194A (ru) | Эфиры n-алкилкарбониламинокислот и n-алкилкарбониламинолактоны и их применение | |
EP3052475A1 (en) | Pharmaceutical use of 3-benzylsulfonylpropionitrile | |
Wyllie et al. | Practical and effective treatment of premature ejaculation (PE) with a lidocaine-prilocaine spray |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003510106 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/000007 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2453572 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002317182 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002745439 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10482457 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002745439 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |